twenti
antivir
drug
half
current
approv
formal
licens
clinic
use
treatment
human
immunodefici
viru
infect
acquir
immun
defici
syndrom
other
use
treatment
herpesviru
eg
herp
simplex
viru
varicella
zoster
viru
cytomegalo
viru
hepat
b
viru
hepat
c
viru
influenza
viru
infect
recent
endeavour
focuss
develop
improv
antivir
therapi
viru
infect
alreadi
prove
amen
antivir
drug
treatment
well
viru
infect
present
antivir
drug
formal
approv
ie
human
papilloma
virus
adenovirus
human
herpesviru
type
poxvirus
sever
acut
respiratori
syndrom
coronaviru
hemorrhag
fever
virus
antivir
drug
formal
licens
clinic
use
use
treatment
human
immunodefici
viru
hiv
infect
acquir
immun
defici
syndrom
aid
antihiv
compound
fall
five
categori
first
nucleosid
revers
transcriptas
inhibitor
nrti
zidovudin
didanosin
zalcitabin
stavudin
lamivudin
abacavir
emtricitabin
second
nucleotid
revers
transcriptas
inhibitor
tenofovir
disoproxil
fumar
third
nonnucleosid
revers
transcriptas
inhibitor
nnrti
nevirapin
delavirdin
efavirenz
fourth
proteas
inhibitor
pi
saquinavir
ritonavir
indinavir
nelfinavir
amprenavir
lopinavir
combin
ratio
ritonavir
atazanavir
fosamprenavir
fifth
fusion
inhibitor
enfuvirtid
lamivudin
adefovir
dipivoxil
approv
treatment
hepat
b
viru
infect
antiherpesviru
agent
acyclovir
valaciclovir
famciclovir
brivudin
penciclovir
idoxuridin
trifluridin
use
latter
three
topic
treatment
herp
simplex
viru
hsv
andor
varicellazost
viru
vzv
infect
ganciclovir
valganciclovir
foscarnet
cidofovir
fomivirsen
latter
intravitr
inject
proven
use
treatment
cytomegaloviru
cmv
infect
immunocompromis
patient
ie
aid
patient
cmv
retin
follow
progress
amantadin
rimantadin
matrix
protein
blocker
onto
market
neuraminidas
inhibitor
zanamivir
oseltamivir
becom
avail
therapi
prophylaxi
influenza
viru
infect
ribavirin
use
topic
aerosol
treatment
respiratori
syncyti
viru
infect
combin
ribavirin
pegyl
interferona
receiv
increas
accept
treatment
hepaciviru
hepat
c
viru
hcv
infect
howev
sever
import
viru
infect
antivir
drug
develop
even
amen
antivir
drug
therapi
still
consider
room
improv
term
higher
potenc
andor
increas
select
safeti
review
highlight
recent
approach
toward
treatment
human
papilloma
viru
hpv
infect
adenoviru
infect
hsv
vzv
infect
human
herpesviru
type
infect
poxviru
infect
hepaciviru
infect
corona
viru
infect
ie
sever
acut
respiratori
syndrom
sar
influenza
viru
infect
hemorrhag
fever
viru
infect
hiv
infect
aid
although
cidofovir
also
known
cytosin
hpmpc
figur
formal
licens
intraven
treatment
cmv
retin
aid
patient
label
use
success
system
topic
treatment
sever
dna
viru
infect
polyoma
papilloma
adeno
herpesand
poxviru
particularli
strike
effect
obtain
cidofovir
topic
gel
applic
direct
intralesion
inject
treatment
hpvassoci
papillomat
lesion
hypopharyng
esophag
papilloma
laryng
papilloma
recurr
respiratori
papillomatosi
children
anogenit
hpv
infect
ie
condylomata
acuminata
bowenoid
papulosi
perian
intraepitheli
neoplasia
cervic
vulvar
intraepitheli
neoplasia
grade
iii
recalcitr
wart
includ
plantar
wart
mucocutan
hpv
lesion
respond
convent
therapi
case
virtual
complet
durabl
resolut
lesion
achiev
follow
applic
cidofovir
gel
cream
although
compel
evid
effect
cidofovir
hpv
infect
stem
vivo
observ
increas
number
patient
vitro
experi
hpvinfect
keratinocyt
ascertain
cidofovir
specif
kill
hpvposit
cell
induct
apoptosi
effect
might
relat
abil
cidofovir
restor
function
tumor
suppressor
protein
prb
neutral
oncoprotein
respect
hpvinfect
cell
addit
cidofovir
sever
acycl
nucleosid
phosphon
exampl
guanin
pmeg
figur
n
cpr
pmedap
figur
like
cidofovir
abl
specif
induc
apoptosi
hpvinfect
keratinocyt
pmeg
cpr
pmedap
current
investig
potenti
treatment
hpvassoci
papillomat
lesion
adenoviru
infect
immunocompet
individu
gener
selflimit
immunocompromis
patient
particular
allogen
hematopoiet
stem
cell
transplant
recipi
adenoviru
infect
sever
lifethreaten
present
cidofovir
hpmpc
appear
licens
antivir
drug
success
use
treat
adenoviru
infect
addit
cidofovir
acycl
nucleosid
phosphon
adenin
hpmpa
figur
propoxi
pyrimidin
hpmpodapi
figur
prove
potent
select
inhibitor
vitro
replic
adenovirus
also
acycl
nucleosid
purin
dideoxynucleosid
analogu
zalcitabin
dideoxycytidin
ddc
alovudin
dideoxythymidin
also
known
fddt
flt
found
inhibit
vitro
adenoviru
replic
wherea
antiadenoviru
activ
observ
sever
antivir
compound
ribavirin
foscarnet
acyclovir
penciclovir
brivudin
might
worthwhil
examin
hpmpa
hpmpodapi
ddc
flt
experiment
clinic
orient
studi
also
ether
lipid
ester
ie
hexadecyloxypropyl
hdp
octadecyloxyethyl
ode
prodrug
cidofovir
hpmpc
hpmpa
evalu
futur
potenti
treat
adenoviru
infect
human
compound
found
inhibit
adenoviru
replic
vitro
significantli
lower
concentr
significantli
higher
select
indic
note
parent
compound
hpmpc
hpmpa
standard
antivir
drug
current
use
treatment
hsv
andor
vzv
infect
includ
acyclovir
valaciclovir
oral
prodrug
acyclovir
famciclovir
oral
prodrug
penciclovir
brivudin
bvdu
latter
avail
european
countri
although
exquisit
activ
vzv
use
restrict
patient
herp
zoster
infect
bvdu
administ
concomitantli
cytostat
agent
use
treatment
certain
cancer
releas
degrad
product
bvu
bvdu
potenti
toxic
inhibit
dihydropyrimidin
dehydrogenas
key
enzym
degrad
newli
discov
bicycl
furo
pyrimidin
nucleosid
analogu
bcna
ie
cf
cf
cf
figur
cf
figur
drawback
although
bcna
proven
activ
cf
cf
activ
vzv
bvdu
unlik
enhanc
toxic
two
reason
first
degrad
free
pyrimidin
base
second
latter
shown
interfer
dihydropyrimidin
dehydrogenas
initi
catabol
bcna
extrem
select
antivzv
activ
inhibit
vzv
replic
replic
virus
hsv
select
index
ratio
cytotox
concentr
inhibitori
concentr
viral
replic
excess
bcna
offer
unpreced
potenti
treatment
vzv
infect
new
antihsv
agent
target
viral
helicaseprimas
complex
thiazolylphenyl
deriv
bil
especi
bay
figur
recent
report
vivo
efficaci
anim
model
infect
compound
appear
function
enhanc
affin
helicaseprimas
complex
hsv
dna
complex
compris
three
viral
protein
hsv
gene
product
togeth
unwind
doublestrand
viral
dna
gener
primer
templat
dna
synthesi
viral
dna
polymeras
claim
antivir
potenc
superior
compound
current
use
treatment
hsv
infect
valid
pursuit
helicaseprimas
inhibitor
treatment
hsv
infect
extens
approach
involv
molecul
interact
format
hsv
dna
polymeras
complex
ie
inhibit
interact
proteinprotein
interact
constitut
new
target
design
antivir
agent
explor
potenti
antivir
drug
human
herpesviru
type
infect
like
cmv
increasingli
recogn
import
pathogen
immunocompromis
patient
might
caus
lifethreaten
complic
howev
unlik
cmv
infect
compound
formal
approv
treatment
infect
drug
clinic
use
use
cmv
therapi
prophylaxi
consist
ganciclovir
valganciclovir
lesser
extent
acyclovir
valaciclovir
cidofovir
foscarnet
compound
target
viral
dna
polymeras
consid
follow
phosphoryl
substrat
analogu
except
foscarnet
act
pyrophosph
analogu
anoth
class
compound
act
nonnucleosid
inhibitor
herpesviru
dna
polymeras
exhibit
broadspectrum
antivir
activ
human
herpesvirus
includ
hcmv
except
lack
activ
owe
singl
amino
acid
chang
conserv
domain
iii
dna
polymeras
recent
discov
new
antivir
agent
figur
demonstr
potent
select
vitro
activ
three
human
bherpesvirus
cmv
compar
ganciclovir
foscarnet
show
higher
potenc
lower
cytotox
howev
antivir
action
appear
celldepend
must
target
event
follow
viral
entri
preced
viral
dna
replic
also
found
inhibit
total
cellular
protein
tyrosin
kinas
activ
conclud
exert
activ
inhibit
cellular
process
crucial
earli
stage
viral
replic
might
involv
protein
tyrosin
kinas
activ
famili
poxvirida
encompass
orthopoxvirus
eg
variola
vaccinia
cowpox
monkeypox
camelpox
parapoxvirus
eg
orf
molluscivirus
eg
molluscum
contagiosum
viru
sever
nucleosid
analogu
ie
idoxuridin
nucleotid
analogu
includ
hpmpc
cidofovir
hpmpodapi
effect
variou
anim
model
poxviru
infect
particular
cidofovir
shown
high
efficaci
protect
mice
lethal
respiratori
infect
either
vaccinia
cowpox
even
administr
singl
system
intraperiton
intranas
aerosol
dose
cidofovir
demonstr
high
effect
treatment
dissemin
progress
vaccinia
athymicnud
mice
human
cidofovir
use
success
topic
intraven
rout
treatment
orf
recalcitr
molluscum
contagiosum
immunocompromis
patient
review
de
clercq
data
indic
cidofovir
effect
therapi
prophylaxi
smallpox
variola
relat
poxvirus
human
well
treatment
complic
vaccinia
aris
immunocompromis
patient
inadvert
inocul
smallpox
vaccin
vaccinia
howev
cidofovir
phosphon
analogu
limit
oral
bioavail
outbreak
smallpox
would
use
oral
activ
drug
hand
could
selfadminist
therefor
hexadecyloxypropylcidofovir
hdpcdv
octadecyloxyethylcidofovir
odecdv
design
develop
potenti
oral
drug
prophylaxi
treatment
variola
viru
infect
figur
alkyloxyalkyl
ester
cidofovir
found
significantli
enhanc
inhibit
orthopoxviru
replic
ie
vaccinia
cowpox
vitro
given
oral
hdpcdv
odecdv
effect
cidofovir
administ
parenter
treatment
vaccinia
cowpox
infect
hdpcdv
also
proven
effect
treatment
lethal
vaccinia
viru
respiratori
infect
mice
furthermor
administ
oral
hdpcdv
odecdv
prove
highli
efficaci
lethal
mousepox
aerosol
ectromelia
viru
model
attest
potenti
use
lipid
prodrug
cidofovir
oral
therapi
prophylaxi
poxviru
infect
present
therapi
chronic
hepat
c
consist
pegyl
interferon
ifn
mg
weekli
combin
ribavirin
mg
daili
treatment
regimen
produc
sustain
virolog
respons
least
patient
infect
hcv
genotyp
patient
infect
anoth
genotyp
hcv
patient
infect
hcv
genotyp
treat
least
week
length
time
might
reduc
week
patient
infect
hcv
genotyp
combin
ribavirin
assum
act
immunomodul
wherea
ifn
would
act
antivir
agent
target
phosphoprotein
encod
nonstructur
gene
hcv
genom
addit
gene
product
nonstructur
protein
ntpasehelicas
serin
proteas
rnadepend
rna
polymeras
rdrp
also
known
rna
replicas
could
envisag
target
inhibitor
hcv
replic
proofofprincipl
compound
target
proteas
could
reduc
plasma
concentr
hcv
rna
provid
proteas
inhibitor
biln
figur
equal
attract
target
develop
hcv
inhibitor
hcv
rna
replicas
highli
select
antivir
agent
target
viral
rna
replicas
describ
inhibit
replic
bovin
viral
diarrhoea
viru
bvdv
pestiviru
could
consid
surrog
viru
hcv
recent
describ
novel
seri
compound
eg
prototyp
methyl
pyridin
also
known
bpip
figur
act
nonnucleosid
rdrp
inhibitor
inhibit
replic
bvdv
high
effici
class
compound
base
differ
structureact
relationship
new
congen
deriv
act
equal
effici
hcv
replic
futur
treatment
hcv
infect
nonnucleosid
rdrp
inhibitor
like
combin
nucleosid
rdrp
inhibitor
exampl
latter
albeit
rel
weak
inhibitor
bvdv
hcv
n
hydroxycytidin
sever
hcv
protein
encod
sar
coronaviru
sarscov
could
consid
target
chemotherapeut
intervent
spike
protein
sarscov
main
proteas
also
known
proteas
ntpasehelicas
rnadepend
rna
polymeras
rdrp
possibl
viral
cellular
proteinmedi
process
sarscov
protein
mediat
infect
permiss
cell
control
interact
domain
cell
express
sarscov
receptor
angiotensinconvert
enzym
acid
fragment
protein
correspond
amino
acid
residu
found
block
proteinmedi
infect
human
monoclon
antibodi
domain
found
neutral
sarscov
block
associ
sarscov
receptor
addit
ctype
lectin
also
call
lsign
identifi
recent
receptor
sarscov
well
envelop
virus
includ
ebola
thu
like
might
target
block
sarscov
infect
also
extent
fusogen
mechan
hiv
similar
sarscov
eg
regard
heptad
repeat
interact
sixhelix
bundl
format
feasibl
develop
sarscov
fusion
inhibitor
analog
enfuvirtid
use
treatment
hiv
knowledg
crystal
structur
sarscov
main
proteas
offer
solid
basi
ration
drug
design
sarscov
proteas
inhibitor
potenti
target
exampl
ntpasehelicas
rna
replicas
structur
basi
still
elabor
meanwhil
varieti
old
new
compound
report
inhibit
vitro
replic
sarscov
present
rel
high
concentr
mm
shortag
small
molecul
activ
mm
concentr
rang
whether
molecul
prevent
suppress
infect
vivo
remain
establish
sar
reemerg
two
year
first
apparit
subsequ
disappear
perhap
pegyl
form
ifna
would
logic
choic
prophylaxi
earli
postexposur
manag
sar
ifna
inhibit
sarscov
replic
vitro
pegyl
ifna
recent
shown
reduc
viral
replic
excret
decreas
viral
antigen
express
pneumocyt
reduc
attend
pulmonari
damag
cynomolgu
macaqu
infect
experiment
sarscov
given
persist
epidem
influenza
strain
h
n
h
n
threat
pandem
avian
influenza
strain
h
n
combin
fact
vaccin
avail
latter
much
emphasi
recent
put
chemotherapi
prophylaxi
influenza
viru
infect
principl
three
class
compound
could
consid
purpos
ribavirin
amantadin
rimantadin
neuraminidas
inhibitor
zanamivir
oseltamivir
figur
although
ribavirin
activ
vitro
replic
influenza
viru
activ
pursu
manag
influenza
viru
infect
vivo
instead
develop
inhal
smallparticl
aerosol
formul
patient
primarili
young
infant
high
risk
bronchopneumon
caus
respiratori
syncyti
viru
infect
matrix
hydrogen
ion
channel
blocker
amantadin
rimantadin
use
mani
year
prophylaxi
therapi
influenza
viru
infect
howev
past
gain
wide
accept
mainli
follow
reason
rapidli
lead
emerg
drugresist
viru
mutant
activ
influenza
b
demonstr
particularli
amantadin
exert
side
effect
central
nervou
system
present
neuraminidas
inhibitor
zanamivir
oseltamivir
practic
avail
therapi
andor
prophylaxi
influenza
b
viru
infect
influenza
viru
adopt
uniqu
replic
strategi
use
one
surfac
glycoprotein
hemagglutinin
h
bind
target
cell
receptor
contain
termin
sialic
acid
nacetylneuramin
acid
anoth
surfac
glycoprotein
neuraminidas
cleav
termin
sialic
acid
host
cell
receptor
allow
viru
particl
leav
cell
viral
replic
cycl
complet
neuraminidas
inhibitor
block
releas
newli
form
viru
particl
thu
prevent
spread
host
cell
benefit
offer
neuraminidas
inhibitor
substanti
use
therapeut
lead
reduct
ill
day
reduct
viru
transmiss
household
healthcar
contact
reduct
frequenc
sever
complic
sinus
bronchiti
therefor
decreas
requir
antibiot
use
prophylact
significantli
reduc
number
new
case
influenza
although
resist
neuraminidas
inhibitor
develop
evid
natur
occur
resist
either
zanamivir
oseltamivir
zanamivir
oseltamivir
abl
block
influenza
b
virus
would
theori
also
effect
pandem
influenza
h
n
viru
zanamivir
must
taken
oral
inhal
particular
oseltamivir
conveni
administ
oral
capsul
stockpil
affront
potenti
influenza
pandem
futur
import
hemorrhag
fever
virus
fall
within
famili
flavivirida
ie
yellow
fever
dengu
arenavirida
ie
lassa
junin
machupo
guanarito
sabia
bunyavirida
ie
rift
valley
crimeancongo
hantaan
filovirida
ie
ebola
marburg
prospect
therapi
flaviviru
infect
overwhelm
ribavirin
weak
activ
flavivirus
present
ifna
whether
pegyl
ifn
induc
poli
c
ampligen
offer
appreci
potenti
prophylaxi
andor
therapi
flaviviru
infect
decreas
virusinduc
morbid
paralysi
mortal
caus
progress
enceph
experiment
flaviviru
enceph
model
sever
combin
immunodefici
mice
anoth
approach
base
conjug
phosphorodiamid
morpholino
oligom
argininerich
peptid
increas
cellular
uptak
describ
inhibit
replic
sever
rna
virus
vitro
includ
dengu
viru
type
remain
demonstr
whether
antisens
approach
also
offer
vivo
efficaci
arenavirus
bunyavirus
ribavirin
figur
accredit
efficaci
experiment
anim
model
well
human
latter
case
lassa
fever
variou
mechan
action
propos
explain
antivir
activ
ribavirin
fascin
theori
error
catastroph
accord
hypothesi
ribavirin
would
act
rna
viru
mutagen
forc
rna
viru
gain
lethal
accumul
error
error
catastroph
shown
polioviru
demonstr
rna
virus
hiv
hcv
flavivirus
yellow
fever
paramyxovirus
parainfluenza
predomin
mechan
ribavirin
exert
antivir
activ
vitro
appear
base
inhibit
inosin
dehydrogenas
treatment
ebola
marburg
viru
infect
sadenosylhomocystein
hydrolas
inhibitor
carbocycl
figur
might
worth
pursu
even
administ
singl
dose
first
second
day
infect
found
protect
almost
mice
lethal
ebola
viru
infect
protect
effect
accompani
probabl
mediat
enhanc
product
ifn
ebola
virusinfect
anim
total
differ
approach
toward
treatment
ebola
viru
infect
base
use
recombin
nematod
anticoagul
protein
potent
inhibitor
tissu
factoriniti
blood
coagul
strategi
target
diseas
process
rather
viral
replic
hiv
gener
effort
toward
antivir
drug
develop
viru
recent
year
wit
develop
novel
approach
well
newli
emerg
candid
drug
antihiv
therapi
compound
current
pre
clinic
investig
target
specif
viral
protein
licens
compound
target
specif
novel
viral
protein
target
cellular
protein
also
new
acycl
nucleosid
phosphon
ie
phosphonomethoxi
alkoxi
pyrimidin
pmpodapi
pmeodapi
deoxythreosyl
nucleosid
phosphon
ie
phosphonomethyldeoxythreosyladenin
pmdta
thymin
pmdtt
figur
describ
potent
select
antihiv
agent
compound
cyanovirinn
thiocarboxanilid
activ
pursu
topic
ie
vagin
microbicid
also
plant
lectin
ie
galanthu
nivali
agglutinin
hippeastrum
hybrid
agglutinin
repres
potenti
candid
antihiv
microbicid
show
mark
stabil
rel
low
ph
high
temperatur
prolong
time
period
directli
interact
viral
envelop
prevent
entri
hiv
target
cell
upon
prolong
exposur
cell
cultur
vitro
hiv
hippeastrum
hybrid
agglutinin
galanthu
nivali
agglutinin
viru
acquir
resist
mutat
glycoprotein
predominantli
locat
nglycosyl
asparagin
site
addit
role
topic
microbicid
plant
lectin
might
due
propens
deplet
viral
envelop
glycan
shield
forc
viru
convert
phenotyp
longer
escap
immun
surveil
host
final
highlight
search
new
antihiv
agent
would
like
cite
multidisciplinari
approach
period
year
led
identif
claim
one
potent
antihiv
agent
ever
discov
nnrti
also
known
rilpivirin
chemic
evolut
start
tibo
yield
compound
show
activ
wildtyp
nnrti
mutant
strain
subnanomolar
concentr
discoveri
eman
coordin
multidisciplinari
effort
involv
medicin
chemist
virologist
crystallograph
molecular
model
toxicologist
analyt
chemist
pharmacist
among
other
highlight
import
requir
novel
antihiv
drug
high
antivir
potenc
wildtyp
mutant
virus
high
oral
bioavail
allow
oncedaili
administr
minim
side
effect
eas
synthesi
formul
recent
year
consider
progress
made
toward
treatment
wide
varieti
viru
infect
irrespect
whether
current
amen
antivir
therapi
highlight
review
potenti
cidofovir
acycl
nucleosid
phosphon
treatment
hpvassoci
papillomat
lesion
futur
prospect
treatment
adenoviru
hsv
vzv
infect
potenti
oral
cidofovir
prodrug
prophylaxi
therapi
poxviru
infect
also
discuss
therapeut
approach
present
futur
hcv
infect
antivir
strategi
manag
sar
import
neuraminidas
inhibitor
hand
affront
futur
influenza
viru
epidem
possibl
strategi
prevent
treatment
hemorrhag
fever
viru
infect
identifi
mani
new
candid
antivir
drug
develop
treatment
hiv
infect
aid
also
review
